SAN DIEGO, Sept. 15, 2014 /PRNewswire/ -- Cannalink, Inc.
(OTC Pink Sheets: SUPID) (the "Company"), formerly Superwire,
Inc., announces that it has effected a change of name of the
Company from Superwire, Inc. to Cannalink, Inc. and a 1 for 50
reverse split. The two corporate actions were approved by FINRA
effective September 10, 2014.
The Company maintains its headquarters in San Diego, California and is managed by its
new Chairman and Chief Executive Officer, Robert L. Plomgren. Commenting on the name
change and reverse split Mr. Plomgren stated, "The change of name to Cannalink,
Inc. reflects the Company's intention to enter the cannabis arena
in two significant ways. First, the Company plans to develop and
manufacture a cannabidiol (CBD)-based product for initial
distribution to healthcare practitioners. In furtherance of this
strategy, the Company completed the acquisition of the MigraSpray
product line and assets for $300,000.
MigraSpray is a sublingually administered formula for the effective
treatment and prevention of migraine headaches, which is
distributed through approximately 5,000 healthcare practitioners.
The Company plans to use the MigraSpray technology to develop its
CBD-based product and to initially market the product through
MigraSpray's practitioner distribution platform. Secondly, the
Company intends to offer investment banking, merchant banking and
business consulting services to emerging companies in the medical
marijuana and industrial hemp sector. The reverse split was
necessary to position the Company to accomplish an effective
recapitalization. In addition, within the next 30-days the Company
intends to provide to OTC Markets the necessary disclosures and
financial filings to have its Stop Sign removed. Further details of
the aforementioned actions and business development plans will be
more fully discussed in such filings."
FORWARD-LOOKING DISCLAIMER
This press release may
contain certain forward-looking statements and information, as
defined within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, and is
subject to the Safe Harbor created by those sections. This material
contains statements about expected future events and/or financial
results that are forward-looking in nature and subject to risks and
uncertainties. Such forward-looking statements by definition
involve risks, uncertainties and other factors, which may cause the
actual results, performance or achievements of Cannalink, Inc. to
be materially different from the statements made herein.
LEGAL DISCLOSURE
Cannalink, Inc. does not sell or
distribute any products that are in violation of the United States
Controlled Substances Act (US CSA).
SOURCE Cannalink, Inc.